Addex axes 28 in wake of positive Parkinson's drug study

Soon after unveiling positive trial data from a study of its Parkinson's drug candidate, Switzerland's Addex says it plans to ax 28 staffers in Geneva. "We are implementing these strategic initiatives from a position of strength following our recent positive results in Parkinson's disease levodopa-induced dyskinesia Phase II clinical trials," says CEO Bharatt Chowrira. "We believe that these measures will position Addex for long-term success and help build significant shareholder value." Release

 

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.